

United States Patent and Trademark Office

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

APPLICATION NO.	FI	LING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.	
10/509,506	C	09/28/2004	Yoshio Okamoto	Furuya Case 1414	4041	
23474	7590	12/06/2006		EXAMINER		
		JTELL & TANIS,	THERKORN, ERNEST G			
2026 RAMB KALAMAZ				ART UNIT PAPER NUMBER 1723		
	,					

DATE MAILED: 12/06/2006

Please find below and/or attached an Office communication concerning this application or proceeding.

			./
	Application No.	Applicant(s)	
	10/509,506	OKAMOTO ET AL.	
Office Action Summary	Examiner	Art Unit	
	Ernest G. Therkorn	1723	
The MAILING DATE of this communication Period for Reply	appears on the cover sheet wi	th the correspondence address	
A SHORTENED STATUTORY PERIOD FOR REWHICHEVER IS LONGER, FROM THE MAILING. - Extensions of time may be available under the provisions of 37 CF after SIX (6) MONTHS from the mailing date of this communication. - If NO period for reply is specified above, the maximum statutory properties to reply within the set or extended period for reply will, by some Any reply received by the Office later than three months after the rearned patent term adjustment. See 37 CFR 1.704(b).	G DATE OF THIS COMMUNIC R 1.136(a). In no event, however, may a r n. eriod will apply and will expire SIX (6) MON statute, cause the application to become AB	CATION. apply be timely filed THS from the mailing date of this communication. ANDONED (35 U.S.C. § 133).	
Status			
 1) Responsive to communication(s) filed on 2 2a) This action is FINAL. 2b) 3) Since this application is in condition for all closed in accordance with the practice und 	This action is non-final. owance except for formal matt	•	
·	or an parto quayio, 1000 c.o		•
Disposition of Claims			
4) ☐ Claim(s) 1-14 is/are pending in the applica 4a) Of the above claim(s) 4-8 is/are withdra 5) ☐ Claim(s) is/are allowed. 6) ☐ Claim(s) 1-3 and 9-14 is/are rejected. 7) ☐ Claim(s) is/are objected to. 8) ☐ Claim(s) are subject to restriction a	awn from consideration.		
Application Papers			
9) The specification is objected to by the Examination The drawing(s) filed on is/are: a) Applicant may not request that any objection to Replacement drawing sheet(s) including the country. The oath or declaration is objected to by the	accepted or b) objected to the drawing(s) be held in abeyar orrection is required if the drawing	ce. See 37 CFR 1.85(a). (s) is objected to. See 37 CFR 1.121(d)).
Priority under 35 U.S.C. § 119			
12) Acknowledgment is made of a claim for for a) All b) Some * c) None of: 1. Certified copies of the priority docur 2. Certified copies of the priority docur 3. Copies of the certified copies of the application from the International But * See the attached detailed Office action for a	ments have been received. ments have been received in A priority documents have been ureau (PCT Rule 17.2(a)).	pplication No received in this National Stage	
Attachment(s) 1) Notice of References Cited (PTO-892)	4) 🔲 Interview S	Summary (PTO-413)	
 2) Notice of Draftsperson's Patent Drawing Review (PTO-948) 3) Information Disclosure Statement(s) (PTO/SB/08) Paper No(s)/Mail Date 		s)/Mail Date nformal Patent Application 	

Art Unit: 1723

Claims 1-3 and 9-14 are rejected under 35 U.S.C. 112, second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which applicant regards as the invention. It is not clear what immobilization of polysaccharide of at least 80% is intended to mean. Is each polysaccharide 80% immobilized? Are only 8 of 10 polysaccharides immobilized? Page 9, lines 3-5 from the bottom of the October 2, 2006 specification is directed to immobilization rate which would appear to be a different concept than immobilization. As such, the claims are considered to be indefinite.

Page 2

Claims 1-3 and 9-14 are rejected under 35 U.S.C. 112, first paragraph, as failing to comply with the written description requirement. The claim(s) contains subject matter which was not described in the specification in such a way as to reasonably convey to one skilled in the relevant art that the inventor(s), at the time the application was filed, had possession of the claimed invention. No support can be found for the "immobilization of polysaccharide is at least 80%." Page 9, lines 3-5 from the bottom of the October 2, 2006 specification is directed to immobilization rate which would appear to be a different concept than immobilization. As such, the claims are directed to new matter.

The following is a quotation of the appropriate paragraphs of 35 U.S.C. 102 that form the basis for the rejections under this section made in this Office action:

A person shall be entitled to a patent unless -

⁽b) the invention was patented or described in a printed publication in this or a foreign country or in public use or on sale in this country, more than one year prior to the date of application for patent in the United States.

Art Unit: 1723

The following is a quotation of 35 U.S.C. 103(a) which forms the basis for all obviousness rejections set forth in this Office action:

(a) A patent may not be obtained though the invention is not identically disclosed or described as set forth in section 102 of this title, if the differences between the subject matter sought to be patented and the prior art are such that the subject matter as a whole would have been obvious at the time the invention was made to a person having ordinary skill in the art to which said subject matter pertains. Patentability shall not be negatived by the manner in which the invention was made.

Claims 1-3, 9, 10, 12, and 13 are rejected under 35 U.S.C. 102(B) as anticipated by or, in the alternative, under 35 U.S.C. 103(a) as obvious over either Kimata (U.S. Patent No. 5,302,633) or Japan Patent No. 4-202141 in view of PTO Translation No. 06-3034. PTO Translation No. 06-3034 will serve as a translation for Japan Patent No. 4-202141. The claims are considered to read on either Kimata (U.S. Patent No. 5,302,633) or Japan Patent No. 4-202141 in view of PTO Translation No. 06-3034. However, if a difference exists between the claims and either Kimata (U.S. Patent No. 5,302,633) or Japan Patent No. 4-202141 in view of PTO Translation No. 06-3034, it would reside in optimizing the elements of either Kimata (U.S. Patent No. 5,302,633) or Japan Patent No. 4-202141 in view of PTO Translation No. 06-3034. It would have been obvious to optimize the elements of either Kimata (U.S. Patent No. 5,302,633) or Japan Patent No. 4-202141 in view of PTO Translation No. 06-3034 to enhance separation.

Claim 3 is rejected under 35 U.S.C. 103(a) as being unpatentable over either Kimata (U.S. Patent No. 5,302,633) or Japan Patent No. 4-202141 in view of PTO Translation No. 06-3034 in view of Murakami (E.P. No. 656,333). At best, the claim differs from either Kimata (U.S. Patent No. 5,302,633) or Japan Patent No. 4-202141 in view of PTO Translation No. 06-3034 in reciting the polysaccharide derivative has a

Art Unit: 1723

polymerizable group at position 6. Murakami (E.P. No. 656,333) (page 3, lines 22-24) discloses the 6-position is a desirable location to link polysaccharides. It would have been obvious to have a polysaccharide derivative with a polymerizable group at position 6 in either Kimata (U.S. Patent No. 5,302,633) or Japan Patent No. 4-202141 in view of PTO Translation No. 06-3034 in view of Murakami (E.P. No. 656,333) because Murakami (E.P. No. 656,333) (page 3, lines 22-24) discloses the 6-position is a desirable location to link polysaccharides.

Claims 11 and 14 are rejected under 35 U.S.C. 103(a) as being unpatentable over either Kimata (U.S. Patent No. 5,302,633) or Japan Patent No. 4-202141 in view of PTO Translation No. 06-3034 in view of Oda (U.S. Patent No. 6,117,325). At best, the claims differ from either Kimata (U.S. Patent No. 5,302,633) or Japan Patent No. 4-202141 in view of PTO Translation No. 06-3034 in reciting use of cellulose phenylcarbamate. Oda (U.S. Patent No. 6,117,325) (column 1, lines 36-39) discloses that cellulose phenylcarbamate is commercialized and widely used because of its high optical resolving powers. It would have been obvious to use cellulose phenylcarbamate in either Kimata (U.S. Patent No. 5,302,633) or Japan Patent No. 4-202141 in view of PTO Translation No. 06-3034 in view of Oda (U.S. Patent No. 6,117,325) because Oda (U.S. Patent No. 6,117,325) (column 1, lines 36-39) discloses that cellulose phenylcarbamate is commercialized and widely used because of its high optical resolving powers.

The remarks urge patentability based upon the immobilization of polysaccharide being of at least 80%. However, this term is considered to be both indefinite and

Art Unit: 1723

directed to new matter. Inasmuch as the recited process steps and the process steps of both Kimata (U.S. Patent No. 5,302,633) and Japan Patent No. 4-202141 in view of PTO Translation No. 06-3034 are the same, the immobilization would appear to be the same.

The remarks urge that Kimata (U.S. Patent No. 5,302,633) does not show the use of monomers. However, Kimata (U.S. Patent No. 5,302,633) on column 5, lines 43-53 discloses use of monomers.

The remarks urge that Japan Patent No. 4-202141 in view of PTO Translation No. 06-3034 does not show the use of monomers. However, the PTO Translation No. 06-3034 on page 7, the last sentence of the second paragraph discloses use of monomers.

THIS ACTION IS MADE FINAL. Applicant is reminded of the extension of time policy as set forth in 37 CFR 1.136(a).

A shortened statutory period for reply to this final action is set to expire THREE MONTHS from the mailing date of this action. In the event a first reply is filed within TWO MONTHS of the mailing date of this final action and the advisory action is not mailed until after the end of the THREE-MONTH shortened statutory period, then the shortened statutory period will expire on the date the advisory action is mailed, and any extension fee pursuant to 37 CFR 1.136(a) will be calculated from the mailing date of the advisory action. In no event, however, will the statutory period for reply expire later than SIX MONTHS from the mailing date of this final action.

Art Unit: 1723

Page 6

Any inquiry concerning this communication should be directed to E. Therkorn at telephone number (571) 272-1149. The official fax number is 571-273-8300.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free).

Ernest G. Therkorn Primary Examiner Art Unit 1723

EGT December 4, 2006